Company
LON:SAR
Sareum Holdings (AIM:SAR) is a clinical-stage biotechnology company developing next generation kinase inhibitors for autoimmune disease and cancer. The Company is focused on developing next generation small molecules which modify the activity of the JAK kinase family and have best-in-class potential. Its lead candidate, SDC-1801, simultaneously inhibits TYK2 and JAK1. SDC-1801 is a potential treatment for a range of autoimmune diseases, including psoriasis, and has completed Phase 1 clinical development.
239 stories · page 2 of 12
The observation, which was published online as an Accelerated Article Preview by 'Nature' on December 11, 2020, is consistent with the scientific rationale supporting the company's recent successful UK Research & Innovation (UKRI) grant app
The £174,000 grant will be used to investigate whether the firm's SDC-1801 therapy candidate can help to block an over-active inflammatory response in severe cases
SRA737 is a Checkpoint kinase 1 inhibitor currently in clinical development targeting solid cancers
The grant will be used to fund an investigation into the therapeutic potential of the company's SDC-1801 treatment on coronavirus patients
Company expects to hear this month whether it will receive grant funding for preliminary studies of a coronavirus (COVID-19) anti-inflammatory.
Subject to certain formalities, the company expects the patent will be granted within the next three months
Investors were told that investigational new drug-enabling work would be completed for at least one of its TYK2/JAK1 candidates by the end of the calendar year
Archive
A glance at some of the day's highlights from the Proactive Investors newswire
An approach using selective TYK2/JAK1 inhibitors may lead to the development of a therapy for lupus that does not involve the harmful side effects of systemic immune system suppression
Archive
Sareum Holdings* 0.6p £18.4m (AIM:SAR) Completion of a fundraising in conjunction with an offer via PrimaryBid. The PrimaryBid Offer successfully completed and closed at 9:00 p.m. on 02 June 2020, raising gross proceeds of £303,722.40 at 0.
The group also confirmed it “continues to engage with interested parties regarding the further development and potential commercialisation” of TYK2/JAK1 drugs SDC-1801 and SDC-1802
The presentation will highlight Sareum's two proprietary TYK2/JAK1 kinase inhibitor programmes, SDC-1801 and SDC-1802, targeting autoimmune diseases and cancers, respectively
Archive
Orosur Mining 1.8p £2.9m (AIM:OMI) The South American-focused gold developer and explorer, announced the appointment of Brad George, 54, as Non-Executive Director of the Company with immediate effect. Mr. George is a geoscientist by profess
The deal covers the FLT3+Aurora kinases portfolio, including SAR-20293, a preclinical drug candidate for acute myeloid leukaemia and other blood-borne cancers
Ahead of the company’s annual meeting, chairman Dr Stephen Parker, said that in SDC-1802, the company has discovered a “potent, orally-available, small molecule contributor to the immune-oncology field, which could prove advantageous over t
“There was a good level of interest directed at novel immunotherapy mechanisms ... and we look forward to further discussions with interested parties"
Archive
Set menuAIM:Total number of AIM Companies (Incl Susp):875*Total number of AIM Companies trading:791**as at close of business 14 October 2019Standard List** of Main Market:Total number of Standard List Companies(Incl Susp)
Sareum Holdings' chief executive, Dr Tim Mitchell, will outline the potential of the company’s latest drug to fight a number of cancers when he attends the American Association for Cancer Research on October 29
Sareum is looking to secure commercial licences for the late pre-clinical or early clinical stages of their development
Archive
Set menu AIM: Total number of AIM Companies (Incl Susp): 879* Total number of AIM Companies trading: 795* *as at close of business 23 September 2019
